Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Conclusions: HMPL-523 is well tolerated as a single agent in Chinese patients with R/R B-cell lymphomas. MTD was reached and RP2D was determined to be 600 mg QD. Preliminary anti-tumor activity was observed in indolent lymphomas, including CLL/SLL and FL.DisclosuresZhu: Beijing Cancer Hospital: Employment. Song: Peking University Cancer Hospital (Beijing Cancer Hospital): Employment. Hua: Hutchison Medipharma: Employment. Yang: Hutchison Medipharma: Employment. Yu: Hutchison Medipharma: Employment. Wang: Hutchison Medipharma: Employment. Dai: Hutchison Medipharma: Employment. Su: Hutchison Medipharma: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Zhu, J., Cao, J., Qiu, L., Qi, J., Song, Y., Tu, M., Ji, D., Shen, W., Sun, M., Hua, Y., Yang, C., Yu, C., Wang, J., Dai, G., Su, W. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies Source Type: research